Georgia's Online Cancer Information Center

Find A Treatment Site

Georgia Cancer Center at Augusta University

NCI Designated Program
Georgia Cancer Center at Augusta University
Minority Based Community Clinical Oncology Program (MB-CCOP)
Augusta, Georgia

The Georgia Cancer Center Minority-Based Community Clinical Oncology Program (MB-CCOP) is designed to increase the availability of state-of-the-art cancer treatment and research to minority individuals in their own communities. Establishment of an operational base in this part of Georgia for extending cancer clinical trials and cancer prevention aims to reduce cancer incidence, morbidity, and mortality in minority populations.

The program was created by the National Cancer Institute (NCI) in 1983 and awarded to Augusta University (formerly known as Georgia Regents, the Medical College of Georgia or MCG and Georgia Health Sciences University) in August of 2004. The principal investigator is Anand P. Jillella, MD. The Grant describes the organizational and operational plans intended to provide structure for the effective implementation of multidisciplinary research. African-Americans comprise 42% of newly diagnosed cancer patients at the Georgia Cancer Center. Adult and pediatric cancer clinical trial programs at the Georgia Cancer Center have been successfully enrolling minorities to clinical trials (40% of patients entered are African-Americans). Ultimately, success of the MB-CCOP depends upon the joint efforts of three departments at the Georgia Cancer Center: Adult Hematology/Oncology, Pediatric Hematology/Oncology, and Family Medicine.

(706) 721-1660

Treatment Sites in Georgia

Clinical Trials in Georgia

A Phase 1 / 2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Cancer Type: Unspecified

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma
Cancer Type: Cervical Cancer

A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
Cancer Type: Bone and Soft Tissue (including Sarcoma)

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Cancer Type: Breast Cancer

An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without Chemotherapy, Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Cancer Type: Unspecified

Implementing a Virtual Tobacco Treatment in Community Oncology Practices: “Smoke Free Support Study 2.0”
Cancer Type: Unspecified

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE


Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.